Artivion

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Artivion sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 1 currently recruiting 2 completed later-stage tilt upper quartile by trial count

Artivion: 7 sponsored US clinical trials, 1 recruiting.

Artivion sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Aortic Dissection, with 2 trials.

Upper-quartile sponsor footprint

Artivion sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Where Artivion enrollment is open (later-stage tilt)

1 recruiting of 7 indexed (14% open); 2 completed (29%).

Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Acute Aortic Dissection (2 trials), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Artivion: open-pipeline peers nationwide

Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Artivion sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40% Total trials Recruiting share Artivion3M4Life Research89bioAbbott Diagnostics DivisionAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRxAlaska Blind Child Discovery
Artivion sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Artivion sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

What to do with this Artivion page

7 registered trials is a research-attention snapshot, not an endorsement of Artivion or any single study.

  • 1 of Artivion's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Acute Aortic Dissection is the condition Artivion studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Aortic Dissection trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Artivion pipeline card: 7 registered trials from official public datasets.Report a data error.